Wipfli Financial Advisors LLC Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG)

Wipfli Financial Advisors LLC acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXGGet Rating) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 929 shares of the company’s stock, valued at approximately $26,000.

Several other large investors have also bought and sold shares of TXG. Raymond James & Associates boosted its stake in 10x Genomics by 19.3% in the first quarter. Raymond James & Associates now owns 53,009 shares of the company’s stock valued at $4,032,000 after buying an additional 8,570 shares in the last quarter. US Bancorp DE boosted its stake in 10x Genomics by 39.6% in the first quarter. US Bancorp DE now owns 9,711 shares of the company’s stock valued at $739,000 after buying an additional 2,753 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in 10x Genomics by 617.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company’s stock valued at $155,000 after buying an additional 1,761 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in 10x Genomics in the first quarter valued at about $416,000. Finally, BlackRock Inc. boosted its stake in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after buying an additional 1,138,358 shares in the last quarter. 74.34% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

Shares of TXG opened at $47.33 on Friday. 10x Genomics, Inc. has a 1 year low of $23.81 and a 1 year high of $100.00. The company has a market capitalization of $5.42 billion, a price-to-earnings ratio of -31.86 and a beta of 1.67. The business has a 50-day moving average of $37.44 and a 200-day moving average of $35.89.

10x Genomics (NASDAQ:TXGGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. 10x Genomics had a negative return on equity of 21.01% and a negative net margin of 33.20%. The company had revenue of $131.10 million during the quarter, compared to the consensus estimate of $129.13 million. During the same period last year, the company earned ($0.15) earnings per share. The firm’s revenue was up 4.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that 10x Genomics, Inc. will post -1.6 EPS for the current year.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 2,676 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total transaction of $91,171.32. Following the completion of the sale, the chief executive officer now owns 974,926 shares of the company’s stock, valued at $33,215,728.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Justin J. Mcanear sold 1,626 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total transaction of $55,397.82. Following the completion of the sale, the chief financial officer now owns 76,764 shares of the company’s stock, valued at $2,615,349.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Serge Saxonov sold 2,676 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $91,171.32. Following the sale, the chief executive officer now directly owns 974,926 shares of the company’s stock, valued at approximately $33,215,728.82. The disclosure for this sale can be found here. Insiders sold 6,663 shares of company stock worth $227,008 over the last ninety days. 11.08% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TXG shares. Deutsche Bank Aktiengesellschaft started coverage on 10x Genomics in a research note on Tuesday, December 13th. They issued a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group dropped their target price on 10x Genomics from $35.00 to $25.00 and set a “sell” rating for the company in a research report on Thursday, October 13th. Morgan Stanley dropped their target price on 10x Genomics from $70.00 to $64.00 and set an “overweight” rating for the company in a research report on Friday, November 4th. Finally, JPMorgan Chase & Co. dropped their target price on 10x Genomics from $65.00 to $55.00 in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGGet Rating).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.